Clinical Trial Update: Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SHR-1210 (PD-1 antibody) plus apatinib versus SHR-1210 alone as second-line treatment for advanced esophageal squamous cell carcinoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Feng Wang | Conditions: Esophageal Cancer | Phase 3 | Status: UNKNOWN